发明名称 |
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING |
摘要 |
The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs. |
申请公布号 |
WO2013173223(A1) |
申请公布日期 |
2013.11.21 |
申请号 |
WO2013US40764 |
申请日期 |
2013.05.13 |
申请人 |
BRISTOL-MYERS SQUIBB COMPANY |
发明人 |
COGSWELL, JOHN P.;GOLDBERG, STACIE M.;GUPTA, ASHOK K.;JURE-KUNKEL, MARIA;WANG, XI TAO;WIGGINTON, JON M. |
分类号 |
C07K16/28 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|